Patients For Affordable Drugs Action Memo: Cancer Patients Have Questions for Bob Hugin
To: Interested Parties
From: David Mitchell, Cancer Patient & Founder,
Patients For Affordable Drugs Action
Date: October 22, 2018
Re: Cancer Patients Have Questions for Bob Hugin
As a former CEO of a big drug company there is little doubt that, if elected, Bob Hugin would side with the drug industry and let drug prices continue to rise. Cancer patients — myself included — have seen firsthand the lengths he will go to put more money in his own pockets at the expense of patients.
- Hugin sold a drug that cost less than $1 to make for more than $600 — a drug that many blood cancer patients like me need to survive.
- He blocked cheaper generics from coming to market.
- He doubled the price of the 50 year-old drug.
- He forced patients like Pam Holt and Gulay Turan into debt.
- He pocketed more than $100 million for himself.
- Bob Hugin made over $100 million by doubling the price of a 50-year-old drug and blocking cheaper generics from coming to market. How does he explain getting rich off cancer patients like Pam Holt?
- Why did the FDA rank Celgene first among companies blocking generics and label his actions “unfair and exploitive”?
- Does Hugin support bipartisan legislation moving through Congress, the CREATES Act, to stop drug companies from blocking generics from coming to market by employing practices he pioneered?
- Does Hugin support direct Medicare negotiation on the price of prescription drugs?
- Should drug companies be allowed to take a tax break on all those TV ads?
You can read more about my story here, or read our report, “The Truth About Bob Hugin,” to get a better understanding of Hugin’s record exploiting cancer patients.
The bottom line is that Big Pharma CEO Bob Hugin made a killing price gouging cancer victims like Pam Holt. Hugin charged $600 for a pill that costs only $1 to make while he made more than $100 million. New Jersey can’t afford Bob Hugin.
